Literature DB >> 23055022

Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.

Yong-Il Ji1, Bo-Young Lee, Yun-Jeong Kang, Jin-Ok Jo, Sang Ho Lee, Heung Yeol Kim, Young-Ok Kim, Chulmin Lee, Suk Bong Koh, Ari Kim, Ji Young Lee, Min Hyung Jung, Mee Sun Ock, Hee-Jae Cha.   

Abstract

Thymosin β4 (Tβ4), a small acidic actin binding peptide, is overexpressed in a side population of cancer stem cells and CD133-positive colorectal cancer stem cells. In order to understand the relationship between Tβ4 and CD133, we studied the expression patterns of Tβ4 and CD133 in ovarian cancers. The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry. Expression patterns and co-localization of Tβ4 and CD133 were examined by immunofluorescence and confocal laser-scanning microscopy. Tβ4 is overexpressed in primary ovarian cancers, but not in primary stomach cancers, when compared with normal controls. However, Tβ4 levels in metastatic stomach cancers to the ovary are significantly upregulated compared with levels in normal stomachs and primary stomach cancers. These results suggest that Tβ4 levels are related to tumorigenesis in ovarian cancers and metastasis in stomach cancers. The expression of Tβ4 in normal ovaries and normal stomachs was weak, but was co-localized with CD133 expression. Tβ4 expression was also co-localized with CD133 expression in primary ovarian carcinomas, metastatic ovarian cancers from stomach cancers and primary stomach cancers. These data suggest that Tβ4 expression is strongly related to CD133 expression and is a characteristic of stem cells or cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055022     DOI: 10.1007/s12253-012-9574-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  50 in total

1.  Thymosin β4 expression in human tissues and in tumors using tissue microarrays.

Authors:  Jin-Ok Jo; Yun-Jeong Kang; Mee Sun Ock; Hynda K Kleinman; Hee-Kyung Chang; Hee-Jae Cha
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-03

2.  Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population.

Authors:  Sebastian C J Steiniger; Judith A Coppinger; Jörg A Krüger; John Yates; Kim D Janda
Journal:  Stem Cells       Date:  2008-09-18       Impact factor: 6.277

3.  Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells.

Authors:  K M Malinda; A L Goldstein; H K Kleinman
Journal:  FASEB J       Date:  1997-05       Impact factor: 5.191

4.  Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.

Authors:  Zhi Yu Wang; Fu Qing Zeng; Zhao Hui Zhu; Guo Song Jiang; Lei Lv; Feng Wan; Rui Dong; Xing Yuan Xiao; Shi An Xing
Journal:  Urol Oncol       Date:  2010-09-22       Impact factor: 3.498

5.  Increased resistance to apoptosis in cells overexpressing thymosin beta four: A role for focal adhesion kinase pp125FAK.

Authors:  M Niu; V T Nachmias
Journal:  Cell Adhes Commun       Date:  2000-01

6.  Thymosin beta4 accelerates wound healing.

Authors:  K M Malinda; G S Sidhu; H Mani; K Banaudha; R K Maheshwari; A L Goldstein; H K Kleinman
Journal:  J Invest Dermatol       Date:  1999-09       Impact factor: 8.551

7.  Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase.

Authors:  H-C Huang; C-H Hu; M-C Tang; W-S Wang; P-M Chen; Y Su
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

Review 8.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10

9.  Actin-sequestering protein, thymosin-beta-4 (TB4), inhibits caspase-3 activation in paclitaxel-induced tumor cell death.

Authors:  Eun-Yi Moon; Ji-Hee Song; Kyu-Hwan Yang
Journal:  Oncol Res       Date:  2007       Impact factor: 5.574

10.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.

Authors:  Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman
Journal:  Cancer Res       Date:  2009-03-31       Impact factor: 12.701

View more
  7 in total

1.  Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.

Authors:  Ahva Shahabi; Juan Pablo Lewinger; Jie Ren; Craig April; Andy E Sherrod; Joseph G Hacia; Siamak Daneshmand; Inderbir Gill; Jacek K Pinski; Jian-Bing Fan; Mariana C Stern
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.012

Review 2.  Potential role of thymosin Beta 4 in liver fibrosis.

Authors:  Jieun Kim; Youngmi Jung
Journal:  Int J Mol Sci       Date:  2015-05-08       Impact factor: 5.923

3.  Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.

Authors:  Michele Cioffi; Crescenzo D'Alterio; Rosalba Camerlingo; Virginia Tirino; Claudia Consales; Anna Riccio; Caterina Ieranò; Sabrina Chiara Cecere; Nunzia Simona Losito; Stefano Greggi; Sandro Pignata; Giuseppe Pirozzi; Stefania Scala
Journal:  Sci Rep       Date:  2015-05-28       Impact factor: 4.379

4.  Hepatic stellate cells express thymosin Beta 4 in chronically damaged liver.

Authors:  Jieun Kim; Sihyung Wang; Jeongeun Hyun; Steve S Choi; Heejae Cha; Meesun Ock; Youngmi Jung
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

5.  Thymosin beta4 regulates cardiac valve formation via endothelial-mesenchymal transformation in zebrafish embryos.

Authors:  Sun-Hye Shin; Sangkyu Lee; Jong-Sup Bae; Jun-Goo Jee; Hee-Jae Cha; You Mie Lee
Journal:  Mol Cells       Date:  2014-04-08       Impact factor: 5.034

Review 6.  Cancer stem cells (CSCs), cervical CSCs and targeted therapies.

Authors:  Ruixia Huang; Einar K Rofstad
Journal:  Oncotarget       Date:  2017-05-23

7.  Changes in Biomechanical Properties of A375 Cells Due to the Silencing of TMSB4X Expression Are Not Directly Correlated with Alterations in Their Stemness Features.

Authors:  Aleksandra Makowiecka; Ewa Mazurkiewicz; Ewa Mrówczyńska; Natalia Malek; Alice Battistella; Marco Lazzarino; Dorota Nowak; Antonina Joanna Mazur
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.